NO902411L - Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.

Info

Publication number
NO902411L
NO902411L NO90902411A NO902411A NO902411L NO 902411 L NO902411 L NO 902411L NO 90902411 A NO90902411 A NO 90902411A NO 902411 A NO902411 A NO 902411A NO 902411 L NO902411 L NO 902411L
Authority
NO
Norway
Prior art keywords
group
formula
bond
propylamines
preparation
Prior art date
Application number
NO90902411A
Other languages
English (en)
Other versions
NO902411D0 (no
Inventor
Nobert Hauel
Annerose Mauz
Jaques Van Meel
Michael Entzeroth
Rainer Zimmermann
Willi Diederen
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE3917801A external-priority patent/DE3917801A1/de
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of NO902411D0 publication Critical patent/NO902411D0/no
Publication of NO902411L publication Critical patent/NO902411L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Terapeutisk aktive-hydroksy-n-propylaminer med formel. hvor Rer en naftylgruppe eller en eventuelt substituert fenylgruppe, A er en eventuelt substituert alkylengruppe, og Rer en gruppe med formelhvor Rutgjør et hydrogenatom eller en alkylgruppe, Rog Rhver er et hydrogenatom eller sammen utgjor en karbon-karbon-binding, og B er en gruppe med formelhvor Rbetyr en alkylgruppe, et hydrogen- eller halogenatom, betyr en binding, et oksygenatom, en sulfonylgruppe eller en -NH-C0-CHgruppe, hvor -CH_gruppen er forbundet med fenyl-kjernen, Xer et nitrogenatom eller en eventuelt substituert metingruppe, Xer et oksygenatom eller en iminogruppe, og Yer en binding eller en iminogruppe, deres tautomerer, deres enantiomerer og deres syreaddisjonssalter, spesielt for farmasøytisk anvendelse, deres fysiologisk akseptable syreaddisjonssalter med uorganiske eller organiske syrer, som oppviser verdifulle farmakologiske egenskaper, spesielt en samtidig kardioton og beta-blokkerende virkning.Forbindelsene kan benyttes som legemidler.Fremgangsmåter for fremstilling av forbindelsene er beskrevet.,
NO90902411A 1989-06-01 1990-05-31 Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer. NO902411L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3917801A DE3917801A1 (de) 1989-06-01 1989-06-01 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3934436A DE3934436A1 (de) 1989-06-01 1989-10-14 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
NO902411D0 NO902411D0 (no) 1990-05-31
NO902411L true NO902411L (no) 1990-12-03

Family

ID=25881458

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90902411A NO902411L (no) 1989-06-01 1990-05-31 Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.

Country Status (13)

Country Link
US (1) US5135932A (no)
EP (1) EP0400519A1 (no)
JP (1) JPH03236378A (no)
KR (1) KR910000660A (no)
AU (1) AU623262B2 (no)
CA (1) CA2017957A1 (no)
DE (1) DE3934436A1 (no)
FI (1) FI902734A7 (no)
HU (1) HU206201B (no)
IL (1) IL94556A0 (no)
NO (1) NO902411L (no)
NZ (1) NZ233875A (no)
PT (1) PT94213A (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221674A (en) * 1989-06-19 1993-06-22 Teikoku Hormone Mfg. Co., Ltd. Pyridazinone derivatives
HU209388B (en) * 1990-12-27 1994-05-30 Richter Gedeon Vegyeszet Process for producing new 3/2h/-pyridazinones and pharmaceutical compositions comprising same
DE4237656A1 (de) * 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
US6525053B1 (en) 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
JP2002511887A (ja) * 1997-08-22 2002-04-16 アボツト・ラボラトリーズ プロスタグランジンエンドペルオキシドｈシンターゼ生合成阻害薬
KR100489649B1 (ko) * 1998-04-14 2005-09-02 삼성정밀화학 주식회사 (s)-3-치환-2-히드록시프로필아민의제조방법
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
WO2002032897A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US7709677B2 (en) * 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
EP1478625A1 (en) 2002-02-27 2004-11-24 Pfizer Products Inc. Processes and intermediates useful in preparing beta-3-adrenergic receptor agonists
WO2003072573A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
CA2506741A1 (en) * 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure
AU2003300297A1 (en) * 2002-12-23 2004-07-22 Artesian Therapeutics, Inc. CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST Beta-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
US20050075323A1 (en) * 2003-03-05 2005-04-07 Pfizer Inc Beta3 adrenergic receptor agonists and uses thereof
JP2008521805A (ja) * 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物
US20080090827A1 (en) * 2004-11-30 2008-04-17 Artesian Therapeutics, Inc. Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
EP2590937A1 (en) 2010-07-05 2013-05-15 The University Of Nottingham Phenoxypropanol derivatives and their use in treating cardiac and cardiovascular diseases
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
GB201101959D0 (en) * 2011-02-04 2011-03-23 Univ Nottingham Novel ether linked compoundsand improved treatments for cardiac and cardiovascular disease
MX2017007054A (es) 2014-12-03 2018-05-02 Velicept Therapeutics Inc Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
EP3746079A1 (en) 2018-01-31 2020-12-09 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1488330A (en) * 1973-12-19 1977-10-12 Smith Kline French Lab Dihydropyridazinones
ES8101067A1 (es) * 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
DE3023369A1 (de) * 1980-06-23 1982-01-14 Boehringer Mannheim Gmbh, 6800 Mannheim Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3129447A1 (de) * 1981-07-25 1983-02-10 Dr. Karl Thomae Gmbh, 7950 Biberach "neue benztriazole, ihre herstellung und ihre verwendung als arzneimittel"
GB8323553D0 (en) * 1983-09-02 1983-10-05 Smith Kline French Lab Pharmaceutical compositions
DE3505609A1 (de) * 1985-02-19 1986-08-21 Merck Patent Gmbh, 6100 Darmstadt Benzimidazolyl-pyridazinone
FR2584713B1 (fr) * 1985-07-11 1988-09-09 Roussel Uclaf Nouveaux derives de l'indole carboxamide, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant
JPH0629254B2 (ja) * 1986-09-08 1994-04-20 帝国臓器製薬株式会社 ピリダジノン誘導体
NZ222843A (en) * 1986-12-22 1989-10-27 Ortho Pharma Corp Benzoxazinyl- and benzothiazinyl-tetrahydropyridazinones and intermediates, and medicaments
DE3734083A1 (de) * 1987-10-08 1989-04-20 Heumann Pharma Gmbh & Co Benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
NZ234087A (en) * 1989-06-19 1991-08-27 Teikoku Hormone Mfg Co Ltd 2-(3-aryloxy(2-hydroxy-propylamino))-2-methylpropyl- aminophenyl pyridazine derivatives
CA2023026A1 (en) * 1989-08-10 1991-02-11 Thomas N. Wheeler Pyridazinones having cardiotonic and beta blocking activity

Also Published As

Publication number Publication date
FI902734A7 (fi) 1990-12-02
IL94556A0 (en) 1991-03-10
US5135932A (en) 1992-08-04
HU903281D0 (en) 1990-10-28
HU206201B (en) 1992-09-28
AU5612790A (en) 1990-12-06
PT94213A (pt) 1991-02-08
NZ233875A (en) 1991-10-25
KR910000660A (ko) 1991-01-29
AU623262B2 (en) 1992-05-07
EP0400519A1 (de) 1990-12-05
FI902734A0 (fi) 1990-06-01
JPH03236378A (ja) 1991-10-22
DE3934436A1 (de) 1991-04-18
CA2017957A1 (en) 1990-12-01
HUT53885A (en) 1990-12-28
NO902411D0 (no) 1990-05-31

Similar Documents

Publication Publication Date Title
JP4510372B2 (ja) アシルフェニル尿素誘導体、その製造方法及び医薬としてのその使用
US4466972A (en) Benzoxadiazoles and benzothiadiazoles, their preparation and pharmaceutical compositions containing them
DE60003949T2 (de) 5-aryl-1h-1,2,4 triazolverbindungen als cyclooxygenase -2 inhibitoren und dieseenthaltende pharmazeutische zusammensetzungen
NO904839L (no) Fremgangsmaate for fremstilling av benzoxazinderivater.
KR880005092A (ko) 항궤양제로서 유효한 벤즈이미다졸의 신규 유도체
JP4634144B2 (ja) ニトロソ化プロトンポンプ阻害剤、組成物および使用方法
GB1573809A (en) Basically substituted indole derivative and process for their manufacture
NO970511L (no) Nye substituerte oksazolidinoner
NO170760C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive nafthalenderivater
GB1566307A (en) Indole derivatives of amides and amino esters and process for their manufacture
NO163568C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
NO871861L (no) Fremgangsmaate for fremstilling av nye dopamin beta-hydroxylase inhibitorer.
DK225081A (da) Aminopropiophenon-derivater og deres syreadditionssalte fremgangsmaader til deres fremstilling og deres anvendelse som gungicider
GB2023600B (en) Imadazole derivatives process for their preparation and pharmaceutical preparations containing them
AU2005202553A1 (en) Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
ATE124408T1 (de) Heterozyklische aminderivate, deren herstellung und deren verwendung.
DK410879A (da) Fremgangsmaade til fremstilling af en sekundaer eller tertiaer amun
FI872930A0 (fi) Analogiamenetelmä ripulinvastaisten 4-(bentsoyyliamino)piperidiinibutaaniamidijohdannaisten valmistamiseksi
NO165144C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av interne salter av aminopyridiniumhydroksidog deres tilsvarende salter.
NO20013601L (no) Nye morfolinobenzamidsalter
NO158676C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-furyl-3,4-dihydroisokinolin-derivater.
DK666989D0 (da) Carboximidamidderivater, deres anvendelse og fremgangsmaade til deres fremstilling
US4425342A (en) 1-(Substituted) piperazine-4-benzenesulfinamides, compositions and method of use
NO921723L (no) Nye kinolinforbindelser, fremgangsmaate for deres fremstilling og deres terapeutiske anvendelse
NO874958L (no) Analogifremgangsmaate for fremstilling av 1-aryloksy-3-amino-2-propanoler.